Last reviewed · How we verify
tapentadol IR — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
tapentadol IR (tapentadol IR) — Ortho-McNeil Janssen Scientific Affairs, LLC. Tapentadol works through dual mechanisms: mu-opioid receptor agonism and norepinephrine reuptake inhibition to provide centrally-mediated analgesia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| tapentadol IR TARGET | tapentadol IR | Ortho-McNeil Janssen Scientific Affairs, LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- tapentadol IR CI watch — RSS
- tapentadol IR CI watch — Atom
- tapentadol IR CI watch — JSON
- tapentadol IR alone — RSS
Cite this brief
Drug Landscape (2026). tapentadol IR — Competitive Intelligence Brief. https://druglandscape.com/ci/tapentadol-ir. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing